Market Research Report
Tenosynovial Giant Cell Tumors (TSGCTs) - Market Insights, Epidemiology and Market Forecast - 2028
|Published by||DelveInsight Business Research LLP||Product code||915412|
|Published||Content info||169 Pages
Delivery time: 1-2 business days
|Tenosynovial Giant Cell Tumors (TSGCTs) - Market Insights, Epidemiology and Market Forecast - 2028|
|Published: November 1, 2019||Content info: 169 Pages||
DelveInsight's 'Tenosynovial Giant Cell Tumors (TSGCTs)-Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Tenosynovial Giant Cell Tumors (TSGCTs) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Tenosynovial Giant Cell Tumors (TSGCTs) from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2017-2028
Tenosynovial giant cell tumors (TGCT) are a group of neoplastic disorders that involve synovium-lined tendon sheaths, synovial joints, and adjacent soft tissue. They are divided on the basis of their localization and diffuse subtypes. These cell tumor is abnormal growth of tissue derived from the synovium that causes activation of immune cells, specifically macrophages, leading to formation of a mass. These tumors are often classified by their growth pattern (localized or diffused) and location (intra- or extra-articular). Tenosynovial giant cell tumor is the term used in 2013 by the World Health Organization classification. They have previously been known as giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumor of the tendon sheath (PVNTS), extra-articular pigmented villonodular tumor of the tendon sheath or localized or focal nodular synovitis. Tenosynovial giant cell tumors (TGCTs) are locally aggressive, soft tissue lesions characterized by inflammation of the synovial lining among joints and tendons. These neoplasms are thought to arise via overexpression of the colony-stimulating factor 1 receptor.
It is important to differentiate tumor and its type for the better treatment option and for the optimized results. The major diagnosis options are limited and the basic radiographic features are the main point of differentiation for the tenosynovial giant cell tumor. The initiation of the diagnosis is done only with the plain radiograph and tumor is differentiated when masses arise from tendons, commonly of the hand, as they may cause pressure erosions on the underlying bone. The diagnosis is done to estimate the type size and affected area of the tumor. It is known that tenosynovial giant cell tumors are clonal neoplastic tumors driven by overexpression of CSF1. The diagnosis is done to differentiate the tumor being cancerous or giant cell tumor. Tenosynovial giant cell tumor (TSGCT) is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. The various diagnosis techniques involve imaging features (radiography, MRI, computed tomography, ultrasonography, clinical testing, workup, and biopsy).
The DelveInsight Tenosynovial Giant Cell Tumors (TSGCTs) market report gives the thorough understanding of Tenosynovial Giant Cell Tumors (TSGCTs) by including details such as disease introduction, clinical features, classification, etiology, pathogenesis, biomarkers and diagnosis.
According to the National Organization for Rare Disorders (NORD), the incidence of Tenosynovial Giant Cell Tumor (TSGCTs) is estimated to be 1.8 people per one million people in the general population based on a study conducted in the United States in 1980. Tenosynovial giant cell tumors mainly affect individuals between 25 and 40 years of age, with a median age of diagnosis of 30. However, these tumors can affect the elderly and younger children as well.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Tenosynovial Giant Cell Tumors (TSGCTs) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028 for the following aspects:
The disease epidemiology covered in the report is segmented by:
A study conducted by David et al. titled "Tenosynovial Giant Cell Tumor: Case Report and Review" stated that Pigmented Villonodular Synovitis is rare, with an estimated annual incidence of 1.8 patients per million. It usually affects young adults (average age, 35 years) but has a wide age range and is slightly more common in women. It usually affects large joints, especially the knee, which accounts for 75-80% of cases. The hip is the second most common site approximately 15%. It is treated with wide, local excision and total synovectomy or arthroplasty; it has a high local recurrence rate, up to 50%, often with multiple recurrences. Diffuse-type GCT is locally aggressive and recurs in 33-50% of cases, often with multiple recurrences. Giant cell tumor of tendon sheath is generally indolent and is successfully treated by simple excision. However, it recurs approximately 25% of the time.
The incidence rate reveals its rarity for localized type (excluding digits), 10.2 per million person-years and for diffuse-type, and 4.1 per million person-years. TGCT is a monoarticular disease, concerning large joints, typically about the knee, 46% in localized-type and 64-75% in diffuse-type. The male-female ratio is about 1:1.5 for both types, with a median age at the time of TGCT diagnosis of 30-50 years. After surgical resection, high recurrence rates are known, with the localized type up to 50% and the diffuse-type up to 92% was figured out in a study titled "The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life" conducted by Mastboom et al.
This segment of the Tenosynovial Giant Cell Tumors (TSGCTs) report encloses the detailed analysis of late stage (Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of Tenosynovial Giant Cell Tumors (TSGCTs) and awareness of the disease. The overall dynamics of Tenosynovial Giant Cell Tumors (TSGCTs) market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Five Prime Therapeutics, Novartis, and others will significantly increase the market during the forecast period (2019-2028).
Tenosynovial giant cell tumors (TGCT), also known as Pigmented Villonodular Synovitis (PVNS), is a rare disease that arises from the synovium, bursae, and tendon sheaths of young adults between 20 and 40 years of age. Origination and history of trauma remain controversial. TGCT is classified as a localized type or diffuse type according to the extent of synovial involvement and the location. The diffuse type (D-TGCT) usually affects larger joints, is often intra-articular, infiltrative, affecting the entire synovium, and has more aggressive behavior.
The treatment for Tenosynovial Giant Cell Tumors (TSGCTs) majorly includes surgery, which is the main treatment option, but the tumor generally recurs, particularly in pigmented villonodular synovitis, which is the diffuse-type of giant cell tumor. If it remains untreated or if the tumor continually recurs, these tumors can result in damage and degeneration of the affected joint and surrounding tissues or structures. Sometimes, they can cause significant disability. After surgical methods, systemic therapy in the context of a nonlethal tumor can be employed to reduce surgical morbidity and to preserve function and patients' quality of life. Because TGCT is associated with characteristic cytogenetic abnormalities resulting in the overexpression of CSF1, systemic therapies targeting the CSF1/CSF1R axis like imatinib, nilotinib, and others have been tested in patients with locally advanced or relapsed DTGCT.
The treatment of TSGCTs mainly follows a mainstay treatment, i.e., surgery followed by other alternatives, such as Radiation Therapy, Radiosynovectomy, and Systemic Therapies (CSF1 inhibitors and Tyrosine Kinase Inhibitors).
This segment gives a through detail of market trend of each late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Tenosynovial Giant Cell Tumors (TSGCTs) in the 7MM is expected to change from 2019-2028.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of therapies for Tenosynovial Giant Cell Tumors (TSGCTs) such as Cabiralizumab (Five Prime Therapeutics), Nilotinib (Novartis), and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Tenosynovial Giant Cell Tumors (TSGCTs) market.